Monomethylvaline compounds capable of conjugation to ligands

Details Monomethylvaline compounds capable of conjugation to ligands Monomethylvaline compounds capable of conjugation to ligands

2007-08-03

2010-06-29

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07745394

ABSTRACT:
Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

REFERENCES:
patent: 3445518 (1969-05-01), Shavel, Jr. et al.
patent: 4414205 (1983-11-01), Pettit
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4764368 (1988-08-01), Blatter et al.
patent: 4816444 (1989-03-01), Pettit et al.
patent: 4879278 (1989-11-01), Pettit et al.
patent: 4943628 (1990-07-01), Rosen et al.
patent: 4978744 (1990-12-01), Petit et al.
patent: 5122368 (1992-06-01), Greenfield et al.
patent: 5165923 (1992-11-01), Thorpe et al.
patent: 5169774 (1992-12-01), Frankel et al.
patent: 5286637 (1994-02-01), Veronese et al.
patent: 5410024 (1995-04-01), Petit et al.
patent: 5521284 (1996-05-01), Pettit et al.
patent: 5530097 (1996-06-01), Pettit et al.
patent: 5554725 (1996-09-01), Pettit
patent: 5585089 (1996-12-01), Queen et al.
patent: 5599902 (1997-02-01), Pettit et al.
patent: 5629197 (1997-05-01), Ring et al.
patent: 5635483 (1997-06-01), Pettit et al.
patent: 5654399 (1997-08-01), Sakakibara et al.
patent: 5663149 (1997-09-01), Pettit et al.
patent: 5665860 (1997-09-01), Pettit et al.
patent: 5708146 (1998-01-01), Willner et al.
patent: 5714586 (1998-02-01), Kunstmann et al.
patent: 5741892 (1998-04-01), Barlozzari et al.
patent: 5767236 (1998-06-01), Kim et al.
patent: 5767237 (1998-06-01), Sakakibara et al.
patent: 5780588 (1998-07-01), Pettit et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5840699 (1998-11-01), Sakakibara et al.
patent: 5965537 (1999-10-01), Ritter et al.
patent: 6004934 (1999-12-01), Sakakibara et al.
patent: 6033876 (2000-03-01), Lemke et al.
patent: 6034065 (2000-03-01), Pettit et al.
patent: 6048720 (2000-04-01), Dalborg et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6054561 (2000-04-01), Ring
patent: 6124431 (2000-09-01), Sakakibara et al.
patent: 6143721 (2000-11-01), Janssen et al.
patent: 6162930 (2000-12-01), Pinney et al.
patent: 6214345 (2001-04-01), Firestone et al.
patent: 6239104 (2001-05-01), Pettit et al.
patent: 6323315 (2001-11-01), Pettit et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6407213 (2002-06-01), Carter et al.
patent: 6569834 (2003-05-01), Pettit et al.
patent: 6620911 (2003-09-01), Petit et al.
patent: 6639055 (2003-10-01), Carter et al.
patent: 6884869 (2005-04-01), Senter et al.
patent: 6913748 (2005-07-01), Widdison
patent: 7090843 (2006-08-01), Francisco et al.
patent: 7091186 (2006-08-01), Senter et al.
patent: 7097840 (2006-08-01), Erickson et al.
patent: 7098305 (2006-08-01), Deghenghi et al.
patent: 7098308 (2006-08-01), Senter et al.
patent: 7498298 (2009-03-01), Doronina et al.
patent: 2001/0018422 (2001-08-01), Ritter et al.
patent: 2002/0001587 (2002-01-01), Erickson et al.
patent: 2003/0083263 (2003-05-01), Doronina et al.
patent: 2003/0096743 (2003-05-01), Senter et al.
patent: 2003/0130189 (2003-07-01), Senter et al.
patent: 2004/0018194 (2004-01-01), Francisco et al.
patent: 2004/0096392 (2004-05-01), Bhaskar et al.
patent: 2004/0141983 (2004-07-01), Law et al.
patent: 2004/0197325 (2004-10-01), Law et al.
patent: 2004/0235068 (2004-11-01), Levinson
patent: 2005/0009751 (2005-01-01), Senter et al.
patent: 2005/0014687 (2005-01-01), Anderson et al.
patent: 2005/0084449 (2005-04-01), Landes et al.
patent: 2005/0106644 (2005-05-01), Cairns et al.
patent: 2005/0107595 (2005-05-01), Cairns et al.
patent: 2005/0113308 (2005-05-01), Senter et al.
patent: 2005/0123536 (2005-06-01), Law et al.
patent: 2005/0180972 (2005-08-01), Wahl et al.
patent: 2005/0232929 (2005-10-01), Kadkhodayan et al.
patent: 2005/0238649 (2005-10-01), Doronina et al.
patent: 2005/0238650 (2005-10-01), Crowley et al.
patent: 2005/0256030 (2005-11-01), Feng
patent: 2005/0260212 (2005-11-01), Zhang et al.
patent: 2005/0272665 (2005-12-01), Schmid et al.
patent: 2006/0073152 (2006-04-01), Dennis
patent: 2006/0074008 (2006-04-01), Senter et al.
patent: 2006/0128970 (2006-06-01), Bliss et al.
patent: 2006/0182751 (2006-08-01), Gazzard et al.
patent: 2006/0233794 (2006-10-01), Law et al.
patent: 2007/0092520 (2007-04-01), Dennis et al.
patent: 2007/0098715 (2007-05-01), Ettenberg et al.
patent: 2007/0134243 (2007-06-01), Gazzard et al.
patent: 2007/0160617 (2007-07-01), Ma et al.
patent: 2007/0212356 (2007-09-01), Chen et al.
patent: 2007/0258987 (2007-11-01), Francisco et al.
patent: 2114156 (1994-07-01), None
patent: 0 598 129 (1994-05-01), None
patent: 0 695 757 (1996-02-01), None
patent: 0 695 758 (1996-02-01), None
patent: 0 695 759 (1996-02-01), None
patent: 06-234790 (1994-08-01), None
patent: 09-77791 (1997-03-01), None
patent: WO 93/03054 (1993-02-01), None
patent: WO 95/09864 (1995-04-01), None
patent: WO 96/14856 (1996-05-01), None
patent: WO 96/22384 (1996-07-01), None
patent: WO 96/33212 (1996-10-01), None
patent: WO 99/35164 (1999-07-01), None
patent: WO 01/18032 (2001-03-01), None
patent: WO 02/43661 (2002-06-01), None
patent: WO 02/43661 (2002-06-01), None
patent: WO 02/088172 (2002-11-01), None
patent: WO 02/088172 (2002-11-01), None
patent: WO 03/008378 (2003-01-01), None
patent: WO 03/034903 (2003-05-01), None
patent: WO 03/043583 (2003-05-01), None
patent: WO 2004/010957 (2004-03-01), None
patent: WO 2004/032828 (2004-04-01), None
patent: WO 2005/084390 (2005-09-01), None
patent: WO 2006/034488 (2006-03-01), None
patent: WO 2006/071441 (2006-07-01), None
patent: WO 2006/083936 (2006-08-01), None
patent: WO 2007/001851 (2007-01-01), None
patent: WO 2007/030642 (2007-03-01), None
patent: WO 2007/059082 (2007-05-01), None
patent: WO 2007/062138 (2007-05-01), None
patent: WO 2007/070538 (2007-06-01), None
patent: WO 2007/109567 (2007-09-01), None
S.R. Vippagunta, et all Adv. Drug Delivery Rev. (2001)48, pp. 3-26.
Alley et al., “Controlling the location of drug attachment in antibody-drug conjugates,”Proceedings of the AACR, vol. 45, abstract # 627 (2004).
Afar et al., “Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer,”Molecular Cancer Therapeutics, 3(8):921-932 (2004).
Bhaskar et al., “E-Selectin Up-Regulation Allows for Targeted Drug Delivery in Prostate Cancer,”Cancer Research, 63:6387-6394 (2003).
Carter, “Improving the Efficacy of Antibody-Based Cancer Therapies,”Nature Reviews1:118-129 (2001).
Dillman, “Monoclonal Antibodies for Treating Cancer, ”Annals of Internal Medicine111:592-603 (1989).
Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy,”Nature Biotechnology, 21(7):778-784 (2003) + Erratum,Nature Biotechnology, 21(8):941 (2003).
Emery et al., “Humanized monoclonal antibodies for therapeutic applications,”Exp. Opin. Invest. Drugs3(3):241-251 (1994).
Francisco et al., “cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity,”Blood, 102(4):1458-1465 (2003).
Hamblett et al., “Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate,”Proceedings of the AACR, vol. 45, abstract # 624 (2004).
Kline et al., “Novel Antitumor Prodrugs Designed for Activation by Matrix Metalloproteinases-2 and -9,”Molecular Pharmaceutics, 1(1):9-22 (2004).
Klussman et al., “Secondary mAb—vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway,”Bioconjug Chem., 15(4):765-773 (2004).
Law et al., “CD70 is expressed on renal cell carcinoma and is a potential target for tumor cell elimination by antibody-drug conjugates,”Proceedings of the AACR, vol. 45, abstract # 625 (2004).
Mao et al., “EphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer,”Cancer Research, 64:781-788 (2004).
Meyer et al., “Recent Advance

Affiliated with

Also associated with

Rating

Monomethylvaline compounds capable of conjugation to ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Monomethylvaline compounds capable of conjugation to ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monomethylvaline compounds capable of conjugation to ligands will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4156808